Condition: Multiple System Atrophy · Sponsor: Dasher Neuroscience Inc.
This is a Phase 2, double-blind, placebo-controlled, multi-center, Phase II, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and efficacy of Ya-101 in subjects with multiple system atrophy.
This description comes directly from the study's public registry record.
Email contact via Dasher Neuroscience Inc. · 857-468-9328 · info@dasherneuroscience.com
Always discuss trial participation with your own doctor first.
| UCLA Health | Los Angeles, California, United States | Recruiting |
| Brigham and Women's Hospital | Boston, Massachusetts, United States | Recruiting |
| Mayo Clinic | Rochester, Minnesota, United States | Recruiting |
| Columbia University Irving medical center | New York, New York, United States | Recruiting |
| Vanderbilt University Medical Center | Nashville, Tennessee, United States | Recruiting |
| Baylor College of Medicine | Houston, Texas, United States | Recruiting |
| Juntendo University Hospital | Tokyo, Japan | Recruiting |
| National Taiwan University Hospital | Taipei, Taiwan | Recruiting |
| National Taiwan University Hospital Cancer Center | Taipei, Taiwan | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06848231